言語を選択

HLA-A*0201 & B2M & p53 (HMTEVVRHC)

HLA-A*0201 & B2M & p53 (HMTEVVRHC) 製品リスト

属性
Protein (2)
製品ライブラリ
オンライン (2)
種
Human (2)
タグ
His Tag & Avi Tag (1)His Tag (1)
マーカー
Biotin-labeled (1)PE Labeled (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
HLP-H82Ef	Human	HEK293	Biotinylated Human HLA-A*02:01&B2M&p53 (HMTEVVRHC) Complex Protein (Monomer, MALS verified)
HLP-HP2He	Human	HEK293	PE-Labeled Human HLA-A*02:01&B2M&p53 (HMTEVVRHC) Tetramer Protein

総数量2

お問い合わせ

HLA-A*0201 & B2M & p53 (HMTEVVRHC)バックグランド

TP53 has been recognized as a tumor suppressor. 50% of cancers carry a TP53 mutation while many others affect other pathway components. High-copy numbers of WT p53 peptide-MHC class I complexes were detected on tumor cells as compared to low copies on normal cells. The Human HLA-A*0201 p53 (HMTEVVRHC) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and HMTEVVRHC peptide of the p53.

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Superoxide dismutase (Ube Industries)	r-hSOD; FKU-871	Phase 2 Clinical	Ube Industries Ltd, Astellas Pharma Inc	Myocardial Ischemia; Diabetic Neuropathies	詳細
Otaplimastat	SP-8203 hydrochloride; SP8203 HCL; SP-8203	Phase 2 Clinical	Shin Poong Pharmaceutical Co Ltd	Stroke	詳細
BMX-010	BMX-010; MnTE-2-PyP; MnTE-2-PyP5+	Phase 2 Clinical	Duke University	Acne Vulgaris; Rosacea; Psoriasis; Dermatitis, Atopic	詳細
APB-102	APB-102; AMT-162	Phase 2 Clinical	University Of Massachusetts Medical School	Amyotrophic Lateral Sclerosis	詳細
Rucosopasem manganese	GC-4711	Phase 1 Clinical	Galera Therapeutics Inc	Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung	詳細
Bis-choline tetrathiomolybdate	ATN-224; WTX-101; ALXN-1840	Phase 1 Clinical	Wilson Therapeutics	Hepatolenticular Degeneration; Multiple Myeloma; Prostatic Neoplasms; Melanoma	詳細
NAS150	AEOL-10150; NAS150; NAS-150	Phase 1 Clinical	Aeolus Pharmaceuticals	Supranuclear Palsy, Progressive; Idiopathic Pulmonary Fibrosis; Neoplasms; Lung Injury	詳細
RAG-17	RAG-17; RAG17	Phase 1 Clinical		Amyotrophic Lateral Sclerosis	詳細
NI-005	AP-101 (AL-S Pharma); NI-005	Phase 1 Clinical	Al-S Pharma Ag	Amyotrophic Lateral Sclerosis	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Orgotein		Approved	Gt Biopharma Inc	Ontosein	Spain	Rheumatic Diseases; Cystitis; Radiation Injuries	null	1996-01-01	Cystitis; Radiation Injuries; Rheumatic Diseases	詳細
Cupric Sulfate/Manganese sulfate/Selenious acid/Zinc Sulfate		Approved	American Regent Inc	MULTRYS	United States	Dietary Supplement	American Regent Inc	2020-07-02	Dietary Supplement	詳細
Tofersen	ISIS-333611; BIIB-067; 99mTc-MAG3-BIIB067	Approved	Ludwig Institute For Cancer Research, Ionis Pharmaceuticals Inc	QALSODY	United States	Amyotrophic Lateral Sclerosis	Biogen Ma Inc, Biogen Inc	2023-04-25	Amyotrophic Lateral Sclerosis	詳細